Run-up to participation in ATACH II in Japan.
Year: 2012
Type: article
Abstract: Intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality in Japan. Seventeen Japanese institutions are participating in the Antihypertensive Treatment for Acute Cerebral Hemorrhage (ATACH) II Trial (ClinicalTrials.gov no. NCT01176565; UMIN 000006526). This phase III trial is designed to determine the therapeutic benefit of early intensive systolic blood pressure (BP) lowering for acute hypertension in ICH patients. This report explains the long run-up to reach the start of patient registration in ATACH II in Japan, including our preliminary study, a nationwide survey on antihypertensive treatment for acute ICH patients, a multicenter study for hyperacute BP lowering (the SAMURAI-ICH study), revision of the official Japanese label for intravenous nicardipine, and construction of the infrastructure for the trial.
Source: Europe PMC (PubMed Central)
Authors: K Toyoda, S Sato, M Koga, H Yamamoto, J Nakagawara, E Furui, Y Shiokawa, Y Hasegawa, S Okuda, N Sakai, K Kimura, Y Okada, S Yoshimura, H Hoshino, Y Uesaka, T Nakashima, Y Itoh, T Ueda, T Nishi, J Gotoh, K Nagatsuka, S Arihiro, T Yamaguchi, K Minematsu
Institution: National Cerebral and Cardiovascular Center
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Institutes of Health
OpenAlex ID: W1898721062